Protalix BioTherapeutics (PLX) EBIAT (2016 - 2025)
Historic EBIAT for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $2.4 million.
- Protalix BioTherapeutics' EBIAT fell 2722.5% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 15615.24%. This contributed to the annual value of $2.9 million for FY2024, which is 6472.57% down from last year.
- Per Protalix BioTherapeutics' latest filing, its EBIAT stood at $2.4 million for Q3 2025, which was down 2722.5% from $164000.0 recorded in Q2 2025.
- Protalix BioTherapeutics' EBIAT's 5-year high stood at $19.3 million during Q2 2023, with a 5-year trough of -$11.2 million in Q2 2021.
- Over the past 5 years, Protalix BioTherapeutics' median EBIAT value was -$3.6 million (recorded in 2022), while the average stood at -$1.7 million.
- In the last 5 years, Protalix BioTherapeutics' EBIAT crashed by 219654.09% in 2021 and then soared by 46256.09% in 2023.
- Over the past 5 years, Protalix BioTherapeutics' EBIAT (Quarter) stood at -$6.7 million in 2021, then skyrocketed by 43.9% to -$3.7 million in 2022, then plummeted by 61.6% to -$6.0 million in 2023, then soared by 207.45% to $6.5 million in 2024, then crashed by 63.74% to $2.4 million in 2025.
- Its EBIAT stands at $2.4 million for Q3 2025, versus $164000.0 for Q2 2025 and -$3.6 million for Q1 2025.